Acrivon Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Acrivon Therapeutics has a total shareholder equity of $196.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $214.7M and $17.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$187.45m |
| Equity | US$196.89m |
| Total liabilities | US$17.79m |
| Total assets | US$214.68m |
Recent financial health updates
We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate
Nov 17
Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?
Jul 17Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation
Mar 29Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Oct 05Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Jun 22We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth
Feb 22Recent updates
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis
Dec 12We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate
Nov 17Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
Sep 18Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?
Jul 17Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation
Mar 29Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Oct 05Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Jun 22We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth
Feb 22Financial Position Analysis
Short Term Liabilities: ACRV's short term assets ($189.0M) exceed its short term liabilities ($14.8M).
Long Term Liabilities: ACRV's short term assets ($189.0M) exceed its long term liabilities ($3.0M).
Debt to Equity History and Analysis
Debt Level: ACRV is debt free.
Reducing Debt: ACRV had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACRV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ACRV has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 46.2% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 00:45 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Acrivon Therapeutics, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Evan Seigerman | BMO Capital Markets Equity Research |
| Etzer Darout | BMO Capital Markets Equity Research |
| Emily Bodnar | H.C. Wainwright & Co. |